{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:25:00Z","timestamp":1715646300755},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.2169\/internalmedicine.1621-23","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T22:11:27Z","timestamp":1684275087000},"page":"131-134","source":"Crossref","is-referenced-by-count":0,"title":["Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation"],"prefix":"10.2169","volume":"63","author":[{"given":"Eiko","family":"Kawakami","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazusato","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"},{"name":"Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Egashira","sequence":"additional","affiliation":[{"name":"Department of Regenerative Oral Surgery, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51: 1278-1284, 2012.","DOI":"10.1093\/rheumatology\/ker518"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25: 925-933, 2016.","DOI":"10.1177\/0961203316651748"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65: 25-34, 2011.","DOI":"10.1016\/j.jaad.2010.09.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ono N, Kai K, Maruyama A, et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 58: 786-791, 2019.","DOI":"10.1093\/rheumatology\/key386"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 12: 773352, 2021.","DOI":"10.3389\/fimmu.2021.773352"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64: 1602-1610, 2012.","DOI":"10.1002\/acr.21728"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 78: 776-785, 2018.","DOI":"10.1016\/j.jaad.2017.12.010"},{"key":"8","unstructured":"8. Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76: 1955-1964, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fujisawa T. Management of myositis-associated interstitial lung disease. Medicina (Kaunas) 57: 347, 2021.","DOI":"10.3390\/medicina57040347"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51: 1563-1570, 2012.","DOI":"10.1093\/rheumatology\/kes102"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang C, Du J, Mei X, et al. The value of effective lung ventilation area ratio based on CT image analysis is a new index to predict the shorter outcome of anti-melanoma differentiation-associated protein 5 positive dermatomyositis associated interstitial lung disease: a single-center retrospective study. Front Med (Lausanne) 8: 728487, 2021.","DOI":"10.3389\/fmed.2021.728487"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50: 776-790, 2020.","DOI":"10.1016\/j.semarthrit.2020.03.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Denny MF, Thacker S, Mehta H, et al. Interferon-\u03b1 promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110: 2907-2915, 2007.","DOI":"10.1182\/blood-2007-05-089086"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56: 3759-3769, 2007.","DOI":"10.1002\/art.23035"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int 39: 1971-1981, 2019.","DOI":"10.1007\/s00296-019-04398-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wu W, Guo L, Fu Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol 60: 293-304, 2021.","DOI":"10.1007\/s12016-020-08822-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/1\/63_1621-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:30:12Z","timestamp":1715574612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/1\/63_1621-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1621-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"1621-23"}}